Brand Name Manufacturers

Zoladex by Zeneca

Generic Manufacturers

None

Pharmacology

GnRH agonist. After an initial stimulating phase, the pituitary is desensitized to GnRH, which causes it to stop producing LH, which in turn dramatically decreases gonadal production of hormones within a month.

Delivery

Sustained release subcutaneous injection 3.6, 10.8mg

Typical dosage

Pre-op 3.6mg/month
(3.6mg implant is for 1 month; 10.8 mg implant is for 3 months)

Availability

Approved by U.S. FDA

Indications

Androgen-sensitive prostate cancer

Contraindications

Known hypersensitivity to GnRH, GnRH analogues, or any of the components of the product

Adverse reactions

CNS

Dizziness. Insomnia. Lethargy.

Gastrointestinal

Anorexia. Nausea.

Skin

Sweating.

Other

Congestive heart failure. Fluid retention. Hot flashes. Increased calcium level in blood. Mild to severe allergic reactions. Obstructive pulmonary disease. Ureteral and spinal compression.

Comments